Sunshine Guojian Pharmaceutical (688336.SH) has announced a forecasted net profit of 700 million to 772 million yuan, an increase of 137.73% to 162% compared to the previous year.
San Sheng Guojian (688336.SH) released the annual performance forecast for 2024, with the company expected to achieve...
Sunshine Guojian Pharmaceutical (688336.SH) released its annual performance forecast for 2024, with an estimated net profit attributable to the company's owners of 7 billion to 7.72 billion yuan, an increase of 137.73% to 162.00% year-on-year; it is expected to achieve a net profit attributable to the company's owners after deducting non-recurring gains and losses of 2.39 billion to 2.79 billion yuan, an increase of 15.57% to 34.83% year-on-year.
Related Articles
New Stock Outlook | Cutting Costs, Pressuring Costs, Losing Customers Three Major Cracks Behind the Silicon-Based Intelligent Light Ring
Industrial: Compared to the dot-com bubble, where is the current AI market heading?
New Stock News | Rongtai Pharmaceutical submits a second application to the Hong Kong Stock Exchange, becoming China's third-largest provider of digital marketing and supply chain services for the outpatient pharmaceutical market.
New Stock Outlook | Cutting Costs, Pressuring Costs, Losing Customers Three Major Cracks Behind the Silicon-Based Intelligent Light Ring
Industrial: Compared to the dot-com bubble, where is the current AI market heading?
New Stock News | Rongtai Pharmaceutical submits a second application to the Hong Kong Stock Exchange, becoming China's third-largest provider of digital marketing and supply chain services for the outpatient pharmaceutical market.
